Explore your questions
Get to Know Your Peptide Options
Different peptides have different purposes, evidence, risks, and regulatory status. These descriptions provide context for a consultation; they do not mean every product is available or appropriate for every person.
01 / PEPTIDE OPTIONS
Sermorelin
Sermorelin is a synthetic analogue of growth-hormone-releasing hormone. A consultation can help you understand the exact product, intended use, evidence, and risks in the context of your health.
Important considerationsCompounded sermorelin is not FDA-approved. Historical approval of Geref does not establish approval of a compounded product or the effectiveness of adult anti-aging claims.
02 / PEPTIDE OPTIONS
PT-141 / Bremelanotide
Questions about low sexual desire deserve a thoughtful conversation. The FDA-approved bremelanotide product, Vyleesi, treats acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women when low desire causes distress and is not explained by another condition, medication, or relationship difficulty.
Important considerationsVyleesi is not indicated for men, postmenopausal women, or sexual performance enhancement. It must not be used with uncontrolled high blood pressure or known cardiovascular disease. Potential effects include nausea, temporary blood-pressure increases, flushing, headache, and skin darkening. Compounded PT-141 does not share Vyleesi’s FDA approval. Discuss the exact product, other medicines, and pregnancy considerations with your clinician.
03 / PEPTIDE OPTIONS
BPC-157
BPC-157 is an investigational peptide discussed in research on tissue injury and gastrointestinal conditions. Human evidence is limited, and its safety and effectiveness for these uses have not been established.
Important considerationsBPC-157 is not FDA-approved. FDA has raised concerns about immune reactions, impurities, and insufficient safety information. Laboratory or animal findings should not be treated as proof of healing or recovery benefits in people.
04 / PEPTIDE OPTIONS
CJC-1295 / Ipamorelin
These investigational peptides are studied in relation to growth-hormone signaling. They are sometimes combined, but the exact CJC form and evidence for the specific combination matter.
Important considerationsThe combination is not FDA-approved. Evidence does not establish benefits for healthy aging, sleep, body composition, or exercise recovery. FDA has identified safety concerns, including increased heart rate and blood-vessel dilation with CJC-1295, and uncertainty about injectable ipamorelin safety.
05 / PEPTIDE OPTIONS
KLOW
If you are interested in KLOW, bring the product name and ingredient information to your consultation. Its exact formulation needs to be confirmed before a meaningful discussion of its evidence, risks, or suitability.
Formulation mattersResearch about an individual ingredient does not establish the safety or effectiveness of a blend. Your clinician can review the specific ingredients, product status, uncertainties, and alternatives before any treatment decision.